At the news
? BULLISHIMPACT 8/10 8-K filed Aug 6, 2026 at 21:27 ET
Replimune announced on August 6, 2026 that the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on a PD-1-based regimen. Continued approval is contingent on verification of clinical benefit in the ongoing confirmatory Phase 3 trial IGNYTE-3. This is Replimune's first approved product, validating its RPx platform and opening a ~10,000 addressable-patient market in the U.S.
- FDA granted accelerated approval for TUDRIQEV (RP1) + nivolumab in advanced melanoma after anti-PD-1 progression
- IGNYTE trial (n=91 efficacy-evaluable): ORR 24.2%, median DOR 14.1 months, 86.1% of responders had DOR >6 months
- No grade 4/5 common adverse events; most adverse reactions were grade 1-2 and transient
- Broad label: no prior BRAF requirement, treat superficial/deep/visceral lesions, retreatment allowed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access